Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.07), $0.36 better than the analyst estimate of ($1.43). Revenue for the quarter came in at $18 million versus the consensus estimate of $17.44 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.